22 related articles for article (PubMed ID: 28160352)
1. Relapse and transformation to myelodysplastic syndrome and acute myeloid leukemia following immunosuppressive therapy for aplastic anemia is more common as compared to allogeneic stem cell transplantation with a negative impact on survival.
Chattopadhyay S; Lionel S; Selvarajan S; Devasia AJ; Korula A; Kulkarni U; Aboobacker FN; Lakshmi KM; Srivastava A; Mathews V; Abraham A; George B
Ann Hematol; 2024 Mar; 103(3):749-758. PubMed ID: 38242970
[TBL] [Abstract][Full Text] [Related]
2. Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation.
Wachter F; Pikman Y; Bledsoe J; Kapadia M; Baumeister S; Rowe J; Shimamura A; Place AE; Prockop S; Whangbo J; Lehmann L; Horan J; Pollard J
Clin Case Rep; 2023 Nov; 11(11):e8190. PubMed ID: 38028059
[TBL] [Abstract][Full Text] [Related]
3. The effect of N-acetyl-l-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation.
El-Serafi I; Remberger M; El-Serafi A; Benkessou F; Zheng W; Martell E; Ljungman P; Mattsson J; Hassan M
Sci Rep; 2018 May; 8(1):8293. PubMed ID: 29844459
[TBL] [Abstract][Full Text] [Related]
4. [Clinical analysis of the therapeutic effect of allogeneic hematopoietic stem cell transplantation in 10 cases of childhood myelodysplastic syndrome/myeloproliferative neoplasm].
Sun YN; Hu SY; He HL; Wang Y; Li J; Lu J; Xiao PF; Yao YH; Fan JJ; Lyu H; Ling J; Hu DX; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2018 Feb; 39(2):162-164. PubMed ID: 29562455
[No Abstract] [Full Text] [Related]
5. Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia.
Yoshimi A; Strahm B; Baumann I; Furlan I; Schwarz S; Teigler-Schlegel A; Walther JU; Schlegelberger B; Göhring G; Nöllke P; Führer M; Niemeyer CM
Biol Blood Marrow Transplant; 2014 Mar; 20(3):425-9. PubMed ID: 24316460
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
7. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
8. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
9. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience.
Maher OM; Silva JG; Wu J; Liu D; Cooper LJ; Tarek N; Worth L; Lee DA; Petropoulos D; Franklin AR; Zweidler-Mckay P; Wells RJ; Rondon G; Champlin RE; Tewari P
Pediatr Transplant; 2017 May; 21(3):. PubMed ID: 28160352
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: The Current Landscape and Future Directions.
Sabile J; Pavletic S; Migdady Y
Cancer J; 2023 May-Jun 01; 29(3):179-187. PubMed ID: 37195774
[TBL] [Abstract][Full Text] [Related]
12. Transplantation without pretransplant therapy: Is this a possibility? Insights into providing transplantation at diagnosis for patients with acute leukemia.
Chao NJ
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101108. PubMed ID: 31779981
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
